Liven Pharma Limited has announced its first successful export to the Arab region. The company shared the update in a notice to the Pakistan Stock Exchange (PSX) on Thursday.
The order was received last year and completed this year. This marks a major milestone for the company as it steps into international markets.
Rights Issue and Expansion Plans
Just last month, Liven Pharma unveiled a Rs200 million rights issue plan. The move aims to strengthen its financial base and fund new projects.
According to the disclosure, the company will issue 20 million ordinary shares at Rs10 each. This represents about 21.5% of its existing paid-up capital. As a result, shareholders will get 21.496 rights shares for every 100 shares held.The fresh capital will allow Liven Pharma to expand its operations and enhance production capacity. Therefore, the company hopes to meet rising demand both locally and abroad.
Company Background
Liven Pharma Limited was incorporated in Pakistan on October 21, 1991. Later, on April 30, 1992, it was converted into a public limited company.
Its core business is manufacturing pharmaceuticals and allied products. Over the years, the company has grown steadily in Pakistan’s healthcare market. With its first export completed, Liven Pharma is now looking to strengthen its international presence.
This development shows Pakistan’s pharmaceutical sector moving toward wider regional growth. In addition, it highlights growing investor confidence in the company’s long-term strategy.
